Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIN001 plus pioglitazone to reduce injection frequency in unilateral wet AMD
2018-003817-16Phase 2Terminated
- Sponsor
- Curatis
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KIN001, pioglitazone and pamapimod in exudative macular degeneration (2 arms), sponsored by Curatis. Primary endpoint: Proportion of patients with successful and confirmed extension of injection interval. Started Dec 2018; status: terminated.
02
Drugs
KIN001pioglitazonepamapimod
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2018-003817-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003817-16.